Cargando…

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib

Detalles Bibliográficos
Autores principales:	Breccia, Massimo, Colafigli, Gioia, Quattrocchi, Luisa, Abruzzese, Elisabetta, Alimena, Giuliana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771144/ https://www.ncbi.nlm.nih.gov/pubmed/26977275 http://dx.doi.org/10.4084/MJHID.2016.016

Ejemplares similares

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
por: Molica, Matteo, et al.
Publicado: (2019)

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib
por: Breccia, Massimo, et al.
Publicado: (2017)

Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia
por: Molica, Matteo, et al.
Publicado: (2020)

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
por: Castagnetti, Fausto, et al.
Publicado: (2021)

Systematic review of dasatinib in chronic myeloid leukemia
por: Breccia, Massimo, et al.
Publicado: (2013)

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib
por: Breccia, Massimo, et al.
Publicado: (2008)

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2021)

Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
por: Price, Kimberly E, et al.
Publicado: (2013)

Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation
por: Puzzolo, Maria Cristina, et al.
Publicado: (2022)

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2022)

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
por: Caocci, Giovanni, et al.
Publicado: (2019)

Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia
por: Musumeci, Francesca, et al.
Publicado: (2018)

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features
por: Tusa, Ignazia, et al.
Publicado: (2020)

Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015)

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
por: Luna, A., et al.
Publicado: (2022)

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs
por: Breccia, Massimo, et al.
Publicado: (2014)

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
por: Anagnostou, Theodora, et al.
Publicado: (2017)

Low Incidence Rate of Opportunistic and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late Chronic Phase.
por: Breccia, Massimo, et al.
Publicado: (2011)

P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA
por: Garcia Gutierrez, Valentin, et al.
Publicado: (2023)

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study
por: Caocci, Giovanni, et al.
Publicado: (2020)

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
Publicado: (2018)

S153: MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS
por: José Cuenca Zamora, Ernesto, et al.
Publicado: (2023)

P663: MULTICENTER, PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL COHORT STUDY OF PONATINIB IN PATIENTS WITH CML IN ITALY: LONG-TERM FOLLOW-UP RESULTS OF THE OITI TRIAL
por: Breccia, Massimo, et al.
Publicado: (2023)

Chronic Myeloid Leukemia Data at ASH 2021: A Podcast on Patient Unmet Needs and Later-Line Treatment Developments
por: Breccia, Massimo
Publicado: (2022)

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
por: Korfi, K., et al.
Publicado: (2015)

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients
por: Ricciardi, Maria Rosaria, et al.
Publicado: (2018)

Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations
por: Abruzzese, Elisabetta, et al.
Publicado: (2020)

Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase
por: Lee, Jae Wook, et al.
Publicado: (2021)

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
por: Breccia, Massimo, et al.
Publicado: (2023)

Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached
por: Breccia, Massimo
Publicado: (2020)

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
por: Soverini, Simona, et al.
Publicado: (2019)

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities
por: Ren, Mingqiang, et al.
Publicado: (2012)

BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia
por: Parry, Narissa, et al.
Publicado: (2022)

Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia
por: Houshmand, Mohammad, et al.
Publicado: (2022)

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
por: Breccia, Massimo, et al.
Publicado: (2020)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
por: Molica, Matteo, et al.
Publicado: (2020)

Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis
por: Küçükyurt, Selin, et al.
Publicado: (2023)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
por: Iurlo, Alessandra, et al.
Publicado: (2021)

Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia
por: Latagliata, Roberto, et al.
Publicado: (2016)

A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
por: García-Gutiérrez, Valentin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_asjth30c52rg09pp85sb7qaqe0